Abstract: Oligonucleotides are provided herein that inhibit apolipoprotein(a) (LPA) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with LPA expression.

Abstract: Provided herein are modified DNAzymes, including DNAzymes with overhang sequences not complementary to the target RNA, in particular, overhangs with high G content. Also provided are compositions comprising the DNAzyme; vectors including the DNAzymes; pharmaceutical compositions including the vectors; and methods including any of the above for cleaving a target RNA; inducing cell death; and treating various diseases and disorders.

Abstract: The invention relates to modulating the expression or activity of a gene by modulating the presence of a regulatory element in the corresponding RNA transcript using a compound targeted to a splicing signal in the RNA transcript to induce splice modulation of one or more exons comprising the regulatory element.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the beta-catenin (CTNNB1) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CTNNB1 gene and to methods of preventing and treating a CTNNB1-associated disorder, e.g., cancer, e.g., hepatocellular carcinoma.

Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 2 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein T, Nu, n, and R100 are defined herein.

Abstract: Disclosed herein are siRNAs, hybrid nanoparticles comprising the siRNAs, pharmaceutical compositions comprising the same, and methods of making and using the same to treat neurological diseases and disorders.

Abstract: Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

Abstract: The present invention provides methods for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder that would benefit from reduction in oxalate, and compositions comprising nucleic acid inhibitors, e.g., double stranded ribonucleic acid (dsRNA) agents or single stranded antisense polynucleotide agents targeting lactate dehydrogenase A (LDHA), hydroxyacid oxidase (HAO1) and/or proline dehydrogenase 2 (PRODH2), for treating such subjects.

Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide diamutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.

Abstract: The disclosure relates to a method of treating a disorder of the tyrosine degradation pathway in a subject, and a composition for use in said method. The disclosure also relates to a nucleic acid silencing molecule that reduces the expression of an enzyme involved in the tyrosine degradation pathway.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.

Abstract: Provided herein are compositions and methods for expressing a mutated suppressor of gamma response 1 (SOG1) gene and/or a polynucleotide of interest in a plant or plant part. Compositions can include promoter molecules that initiate spatio-temporal expression of the mutated SOG1 and/or a polynucleotides of interest. The methods and compositions provided herein can enhance homology-directed repair (HDR) or editing uniformity or frequency, and/or reduce transformant chimerism in a plant or plant part. Plants and plant parts comprising the compositions or produced according to the methods are also provided.

Abstract: The present invention provides a method for selecting a promoter that functions in an organelle, the method comprising: (1) the step of preparing sequence information obtained by RNA sequencing analysis; (2) the step of mapping the sequence information prepared in the step (1) onto a sequence of organellar DNA; (3) the step of calculating the amount of change in RNA expression in each region based on the mapping information obtained in the step (2); (4) the step of selecting regions in which the amount of change obtained in the step (3) is within a range of preset reference values; and (5) the step of identifying a region, among the regions selected, as a promoter functioning in an organelle.

Abstract: Method and associated transgenic oil-producing plants, protists, bacteria, and fungi for increasing concentration of target fatty acids for use in food, biofuel, or industrial chemical applications. Modification of organisms to enhance lipase expression induces triacylglycerol (TAG) remodeling to change the composition of stored oils. Lipase converts endogenously synthesized TAG back to diacylglycerols, allowing resynthesis into TAG with different fatty acid compositions using fatty acid assembly enzymes either native to the organism or expressed through additional transgenic modification.

Abstract: The present disclosure relates to genetically modified plant LysM receptors and methods of producing the same. In particular, the present disclosure relates to modified plant LysM receptors including a modified juxtamembrane (JM) zone 4, and optionally further including a modified JM zone 2, a modified JM zone 3, a modified extracellular domain, and/or a modified kinase C-terminus region or a modified kinase N-terminus region. The modified LysM receptors of the present disclosure are either able to able to initiate NFR1-mediated root nodule symbiosis signaling or able to initiate ROS signaling. In addition, the present disclosure relates to genetically modified plants or parts thereof including the genetically modified plant LysM receptors and methods of producing the same. The present disclosure further relates to expression vectors, isolated DNA molecules, or recombinant nucleic acids encoding the genetically modified plant LysM receptors.

Abstract: The present disclosure relates to modified plant LysM receptor polypeptides with modified intracellular domains, specifically, modified ?A motifs and/or modified ?A? motifs in the juxtamembrane domain. The present disclosure further relates to genetically modified plants including the modified plant LysM receptor polypeptides, and methods of producing the same.

Abstract: Spinach (Spinacia oleracea) plants exhibiting resistance to downy mildew disease caused by Peronospora effusa are provided, together with methods of producing, identifying, or selecting plants or germplasm with a downy mildew resistance phenotype. Such plants include spinach plants comprising introgressed genomic regions conferring pest resistance. Compositions, including novel polymorphic markers for detecting plants comprising introgressed loci, are further provided.

Abstract: The field is related to plant breeding and methods of identifying and selecting plants with resistance to Anthracnose stalk rot. Provided are methods to identify novel genes that encode proteins providing plant resistance to Anthracnose stalk rot and uses thereof. These disease resistant genes are useful in the production of resistant plants through breeding, transgenic modification, or genome editing.

Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.

Abstract: The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof.

Abstract: Provided herein are methods of transducing resting or non-activated T cells using CD4-targeted viral vectors.

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.

Abstract: This disclosure provides compositions and methods for altering or changing the tissue tropism, e.g., liver tropism, of adeno-associated viruses (AAV).

Abstract: Disclosed herein are lentiviral plasmid packaging compositions comprising unique mass ratios of four plasmids that are useful in producing lentiviral vectors. Also provided are methods of producing such lentiviral vectors by mixing a complexation solution comprising the lentiviral plasmid packaging composition with a transfection reagent and incubating the mixture for at least 10 minutes. transfecting a eukaryotic host cell with the lentiviral plasmid packaging composition, adding sodium butyrate to the transfected host cells about one day after transfection, and culturing the host cell. Exemplary embodiments of the method comprise a concentration of total plasmid in pg/mL of 0.25-3 and/or a mass ratio of total plasmid mass in pg to the mass of transfection reagent in pg extending from about 1:1 to about 1:3.

Abstract: The disclosure relates to compositions and methods that modify target nucleic acids, as well as methods of detecting nucleic acids. Various compositions are described herein, including compositions comprising endonucleases, endonuclease systems, and chimeric proteins having the endonuclease and a nucleic-acid modulating domain or a nucleic acid modifying domain.

Abstract: The present invention relates to methods for targeted insertion of at least one nucleic acid sequence/s of interest into a target genomic locus of a mammalian cell. More specifically, the methods of the invention are based on using nucleic acid cassettes comprising the nucleic acid sequence/s of interest and at least one recognition signal sequence (RSS), for insertion of the nucleic acid sequence of interest into the target genomic locus that is mediated by RAG-catalyzed recombination. The invention further provides cassettes, vectors and vehicles and cells comprising said cassettes, compositions and uses thereof in immunotherapy.

Abstract: Provided is a method for producing a bioproduct, comprising culturing at least one target microorganism in a target growth medium comprising cells of a strictly anaerobic bacterium, the cells comprising protein at a crude protein concentration of at least 60 wt % of a total dry weight of the cells, wherein at least 50% of a total number of the cells are dead cells.

Abstract: The invention concerns process and plant for the microbial production of hydrogen from the site of hydrocarbonaceous deposit, the process comprising modifying the composition of the deposit through the introduction into or into the vicinity of the deposit of at least one hydrogen producing microorganism, wherein the at least one hydrogen producing microorganism or at least one microbiological condition conducive to the thriving of the microorganism is selected, or its selection is aided, by means of continuous flow methodology, the plant comprising means in the form of continuous flow methodology apparatus for selecting at least one hydrogen producing microorganism and/or for selecting at least one microbiological condition conducive to the thriving of the microorganism; and means for supplying the at least one hydrogen producing microorganism into the hydrocarbonaceous deposit.

Abstract: The present application provides a process and plant for the microbial production of hydrogen from the site of hydrocarbonaceous deposit, the process comprising modifying the composition of the deposit through the introduction into or into the vicinity of the deposit of at least one hydrogen producing microorganism, wherein the at least one hydrogen producing microorganism is provided on site by means of a transportable microbiological incubator, the plant comprising means in the form of a transportable microbiological incubator for generating at least one hydrogen producing microorganism; and means for supplying the at least one at least one hydrogen producing microorganism into the hydrocarbonaceous deposit.

Abstract: The invention is a process and apparatus for producing bioethanol without CO2 emissions by anaerobic fermentation of a synthesis gas, produced by the thermal conversion at high temperature of a feed consisting of municipal solid waste (MSW), agricultural waste or derivatives thereof such as refuse derived fuel (RED) or even industrial waste such as non-recyclable plastic waste or a combination thereof, to which extra hydrogen is added through electrolysis so as to balance the H2/CO ratio, thus maximizing the conversion of the organic components in the fermentation step so as to prevent any emission of CO2 into the atmosphere.

Abstract: The present disclosure features compositions and methods for producing one or more cannabinoids, such as cannabidiolic acid (CBDa), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an enzyme having CBDa synthase (CBDaS) activity.

Abstract: The present invention provides for a method for producing an olefinic ester, the method comprising: (a) providing a host cell capable of producing olefinic ester; and (b) culturing the host cell to produce olefinic ester. In some embodiments, the olefinic ester is isoprenyl acetate. In some embodiments, the olefinic ester is isoprenyl acetate, and the method further comprises: (c) optionally recovering the isoprenyl acetate; (d) optionally (i) deacetylating the isoprenyl acetate into isoprene, and/or (ii) hydrolyzing isoprenyl acetate into isoprenol and dehydrating the isoprenol into isoprene; and, (e) optionally converting the isoprene into 1,4-dimethylcyclooctane (DMCO).

Abstract: The present invention refer to a process for the production of microbial cellulose using a waste textile material, for example 100% cotton or blended cotton/polyester/elastane waste textile, said waste textile material comprising cellulose, comprising the following steps: providing an amount of said waste textile material; pre-treating said waste textile material with an aqueous solution comprising NaOH and urea, to obtain a pre-treated fabric, wherein said step of treating said waste textile with an aqueous solution comprising NaOH and urea is carried out at a temperature ranging from ?25° C. to +30° C.; treating said pre-treated fabric with cellulase enzymes, to convert said cellulose into glucose, whereby a mixture including glucose is obtained; preparing a culture medium comprising said mixture including glucose; inoculating said culture medium with microbial cellulose producing microorganisms; and incubating said microbial cellulose producing microorganisms to obtain microbial cellulose.

Abstract: A glycoside hydrolase, relating to the technical field of enzyme engineering/gene engineering. Provided are an enzyme of a GH112 glycoside hydrolase family, and an application of synthesizing human milk oligosaccharides (HMOs) by using an enzyme of a GH112 glycoside hydrolase family. A synthesis reaction is catalyzed by using the enzyme of the glycoside hydrolase family 112 (GH112) that is classified according to a Carbohydrate-Active-Enzymes (CAZy) database (http://www.cazy.org); and lacto-N-tetraose (LNT) is generated in an aqueous solution comprising lactose and/or galactose and/or galactose-1-phosphate and lacto-N-triose (LNTII). The enzyme of the glycoside hydrolase family 112 (GH112), and the preparation method therefor and the application thereof provided by the present invention have economic and social values.

Abstract: Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time.

Abstract: Described herein are systems for capping nucleic acid. Also described herein are methods for capping nucleic acid with the systems described herein.

Abstract: The present invention relates to the field of genetic engineering and process engineering, and discloses an engineering strain producing cordycepin and its derivative 3?-deoxyinosine, its preparation method and application. The method includes: codon optimizing genes Cm1 and Cm2; gene amplification and fragment recovering; methanol-induced promoter and terminator fragments; and inserting the genes into an expression vector and then transferring to Pichia pastoris for screening to obtain the engineering strain of Pichia pastoris of the present invention. The engineering strain can be applied to production of cordycepin and its derivative. The engineering strain prepared by the preparation method of the present invention has great advantages in producing cordycepin and its derivative.

Abstract: The present invention relates to self-replicating DNA expression vectors comprising elements from Beak and Feather Disease Virus (BFDV), including a BFDV LIR element comprising an origin of replication (Ori), genes encoding a BFDV Rep protein and a heterologous polypeptide of interest under the control of a mammalian promoter, wherein the Rep protein is capable of binding to the Ori to initiate replication of the expression vector. Pharmaceutical compositions and cells comprising the self-replicating vectors are also provided. The self-replicating vectors may be used in methods of inducing an immune response or expressing a polypeptide in a subject, or as an expression system.

Abstract: The present invention relates to a recombinant granular protein suitable for industrial production and a preparation method therefor. The product is prepared by the following method: transfecting a plasmid vector containing an encoding recombinant granular protein sequence to a host cell for expression in the cell, and harvesting and crushing thalli for heating treatment, incubating of urea and sodium chloride and chromatography. The granular size of the product is uniform, and the inter-batch consistency of the granular size is good. The product prepared by the method can reduce the cost of industrial mass production, the method is simple to operate, and the product has low impurity residue and good safety.

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

Abstract: A method for evaluating metabolism of an active compound includes providing a composition comprising a microbiome obtained from a subject that has received an active compound for a period of time sufficient to achieve steady state; forming a mixture of the composition with either the active compound or a deactivated metabolite of the active compound; identifying a change in the mixture, comprising a reduction in the amount of the active compound or deactivated metabolite, presence of the active compound modified by the microbiome or a re-activated active compound; estimating, from the change in the mixture, the ability of the subject's microbiome to process the active compound or deactivated metabolite in the subject and affect the concentration of the active compound in the subject; determining a dosage required to achieve a concentration of the active compound in the subject that is therapeutically effective; and administering to the subject the dosage required.

Abstract: Provided are methods of separating an absorption spectrum into a Rayleigh scattering contribution and an absorption contribution. By performing such separations and removing the influence of Rayleigh scattering, the absorption of a sample can be more accurately measured. Provided are additional methods that involve separating an absorption spectrum into a Rayleigh scattering contribution and an absorption contribution: assessing whether or not a microorganism is present in a biological fluid, assessing the effect of a pharmaceutical drug on a microorganism, and treating a subject suspected of having an infection. Provided are systems and non-transitory computer readable storage media for separating an absorption spectrum into a Rayleigh scattering and an absorption contribution.

Abstract: Provided herein are biomarkers associated with mortality in COVID-19 patients. In particular, provided herein are fecal biomarkers that correlate with elevated risk of mortality in subjects suffering from COVID-19 with severe respiratory insufficiency, and methods of treating COVID-19 based thereon.

Abstract: Provided herein are methods of assessing the presence of microbes in a liquid sample that include assessing an initial integrated scattering intensity of objects (IC0) in the sample and an integrated scattering intensity of the objects at a time t (ICt) from modified images of the liquid sample, and identifying the sample as comprising microbes for (ICt)/(IC0) above a predefined infection threshold TI. Related systems and other aspects are also provided.

Abstract: The bacteria detection device includes a reservoir which stores a bacterial solution containing bacteria, a sensor which is provided on a bottom of the reservoir and configured to detect the bacteria in the bacterial solution stored in the reservoir, and a filter which is placed on a liquid surface of the bacterial solution stored in the reservoir to permeate the bacterial solution. The filter increases the concentration of the bacteria in the bacterial solution present in a detection region of the sensor by permeating the bacterial solution.

Abstract: A galactose rapid quantitative detection system utilizing a test strip containing a concentration of galactose dehydrogenase as the enzyme and a concentration of trehalose as the stabilizer. The system includes a galactose solution composition including a galactose, a buffer and an antioxidant; a test strip, including an enzyme, and a stabilizer; and a meter. The meter includes a power supply unit for providing a signal; a connector for receiving the signal transmitting the signal to the test strip, the signal reacting with the electrochemical information, and the connector transmits the response signal to the meter; a calculation unit for calculating the response signal; an A/D convertor for receiving the response signal from the calculation unit, transforming the response signal into a digital reaction signal; a processor for processing the digital reaction signal; a display for displaying the digital reaction signal; and a digital terminal for receiving the digital reaction signal.

Abstract: The present invention relates to a method of determining the number of copies of one or more RNA molecules in a population of RNA molecules and a method of determining the sequence of one or more RNA molecules in a population of RNA molecules, wherein the methods include a step of converting the population of RNA molecules to a population of DNA molecules comprising one or more base conversion, by error-prone reverse transcription. The present invention also relates to a population of DNA molecules obtained or obtainable by the methods disclosed herein.

Abstract: The present invention relates to a composition for cell lysis and nucleic acid extraction, a nucleic acid extraction method using the same, and a molecular diagnostic method using the same, and specifically, to a composition for cell lysis and nucleic acid extraction, a nucleic acid extraction method using the same, and a molecular diagnostic method using the same, wherein a composition containing an RNase inhibitor is used as a solution for nucleic acid extraction, and steps of heating to specific temperatures are included, whereby it is possible to minimize the time for molecular diagnosis by performing polymerase chain reaction without a separate elution process and purification process, and to reduce the cost of molecular diagnosis by minimizing the use of dedicated devices and consumables in extraction.

Abstract: This disclosure provides methods, compositions and kits for determining if nucleic acids detected in a sample such as a clinical sample are derived from contaminant pathogens or clinically-relevant pathogens.

Abstract: Contemporary gene sequencing techniques, including “Next. Generation Sequencing” techniques, can include sequencing a plurality of fragments of a target polynucleotide. However, the limitations of existing sequencing techniques means that it can be difficult and/or expensive to align the generated read fragments. Methods provided herein include inserting dual polynucleotide ‘bar-codes’ into a target poly nucleotide that remain mechanically connected via a Tinker.’ Tire barcodes can then be ‘grown’ via. a. pool-split-pool process such that polynucleotide fragments that are linked by linkers exhibit the same complete barcode sequence that is different, from the complete barcode sequence exhibited by non-linked polynucleotide fragments. The joined fragments can then be separated and sequenced.